Pharmaceuticals, Biotechnology and Life Sciences
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.
Allergan’s net revenue for the fourth quarter 2016 rose 7 percent to $3.86 billion, mostly driven by better sales of Botox, Linzess and certain other new products.
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
Two remaining late-stage clinical trials testing an experimental Alzheimer’s drug from Denmark’s Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
French biotechnology company Lysogene has kicked off well with its initial public offering on Euronext Paris stock market by raising €22.6 million.
Kingsway Trading of Brooklyn, NY is recalling its 1.06 oz (30g) bottles of “Well Balance Xanthium & Siler Combo (Bi Yan Pian)” Batch No. 130401 & Batch No. 150201 because they contain the presence of undeclared Ephedra Herba (ma huang), an FDA banned item, FDA said.
Zealand Pharma has reported royalty revenue from Sanofi’s sales of Lyxumia (lixisenatide) outside the United States of €0.7 million for Q4 2016 and annual royalty revenue of €3.3 million in 2016.